Unichem lines up ₹350-cr capex

PTI New Delhi | Updated on January 12, 2018 Published on June 08, 2017

Drug firm Unichem Laboratories has lined up a capex of around ₹350 crore for the next two years as it plans to strengthen R&D activity and expand operations in the US market.

The company, which focuses on various therapeutic segments like gastroenterology and cardiology, expects its US revenues to cross $100 million over the next few years. The long term aim of the company is to cross $500 million in revenues from the US operations.

“One major capex is the API expansion, which is going on, the new plant which is coming up as well as on the formulation side and existing API site,” Unichem Laboratories Chief Finance and Compliance Officer Rakesh Parikh said in a analyst call.

Published on June 08, 2017
This article is closed for comments.
Please Email the Editor